Logo image of CERS

CERUS CORP (CERS) Stock Fundamental Analysis

NASDAQ:CERS - US1570851014 - Common Stock

1.31 USD
0 (0%)
Last: 8/28/2025, 4:30:00 PM
1.31 USD
0 (0%)
After Hours: 8/28/2025, 4:30:00 PM
Fundamental Rating

3

Overall CERS gets a fundamental rating of 3 out of 10. We evaluated CERS against 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CERS have multiple concerns. While showing a medium growth rate, CERS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

CERS had negative earnings in the past year.
CERS had a positive operating cash flow in the past year.
CERS had negative earnings in each of the past 5 years.
CERS had negative operating cash flow in 4 of the past 5 years.
CERS Yearly Net Income VS EBIT VS OCF VS FCFCERS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

CERS's Return On Assets of -8.86% is fine compared to the rest of the industry. CERS outperforms 61.62% of its industry peers.
With a Return On Equity value of -34.06%, CERS perfoms like the industry average, outperforming 52.97% of the companies in the same industry.
Industry RankSector Rank
ROA -8.86%
ROE -34.06%
ROIC N/A
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
CERS Yearly ROA, ROE, ROICCERS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

CERS's Gross Margin of 60.94% is fine compared to the rest of the industry. CERS outperforms 61.08% of its industry peers.
In the last couple of years the Gross Margin of CERS has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CERS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
CERS Yearly Profit, Operating, Gross MarginsCERS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

CERS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CERS has been increased compared to 1 year ago.
The number of shares outstanding for CERS has been increased compared to 5 years ago.
CERS has a worse debt/assets ratio than last year.
CERS Yearly Shares OutstandingCERS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
CERS Yearly Total Debt VS Total AssetsCERS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

CERS has an Altman-Z score of -4.82. This is a bad value and indicates that CERS is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -4.82, CERS is not doing good in the industry: 69.19% of the companies in the same industry are doing better.
CERS has a debt to FCF ratio of 24.80. This is a negative value and a sign of low solvency as CERS would need 24.80 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 24.80, CERS is doing good in the industry, outperforming 69.73% of the companies in the same industry.
CERS has a Debt/Equity ratio of 1.02. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of CERS (1.02) is worse than 79.46% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF 24.8
Altman-Z -4.82
ROIC/WACCN/A
WACC8.9%
CERS Yearly LT Debt VS Equity VS FCFCERS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

CERS has a Current Ratio of 2.00. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 2.00, CERS is not doing good in the industry: 64.86% of the companies in the same industry are doing better.
CERS has a Quick Ratio of 1.35. This is a normal value and indicates that CERS is financially healthy and should not expect problems in meeting its short term obligations.
CERS has a worse Quick ratio (1.35) than 63.24% of its industry peers.
Industry RankSector Rank
Current Ratio 2
Quick Ratio 1.35
CERS Yearly Current Assets VS Current LiabilitesCERS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

CERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.67%, which is quite good.
Looking at the last year, CERS shows a quite strong growth in Revenue. The Revenue has grown by 11.25% in the last year.
CERS shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.50% yearly.
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)11.25%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%16.34%

3.2 Future

Based on estimates for the next years, CERS will show a very strong growth in Earnings Per Share. The EPS will grow by 28.85% on average per year.
CERS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.46% yearly.
EPS Next Y-5.09%
EPS Next 2Y22.7%
EPS Next 3Y28.85%
EPS Next 5YN/A
Revenue Next Year29.28%
Revenue Next 2Y18.91%
Revenue Next 3Y16.46%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CERS Yearly Revenue VS EstimatesCERS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M 200M 250M
CERS Yearly EPS VS EstimatesCERS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CERS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CERS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERS Price Earnings VS Forward Price EarningsCERS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

71.35% of the companies in the same industry are more expensive than CERS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 73.36
EV/EBITDA N/A
CERS Per share dataCERS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

A more expensive valuation may be justified as CERS's earnings are expected to grow with 28.85% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.7%
EPS Next 3Y28.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CERS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERUS CORP

NASDAQ:CERS (8/28/2025, 4:30:00 PM)

After market: 1.31 0 (0%)

1.31

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)10-28 2025-10-28/amc
Inst Owners73.45%
Inst Owner Change-3.19%
Ins Owners2.97%
Ins Owner Change20.57%
Market Cap251.13M
Analysts80
Price Target4.76 (263.36%)
Short Float %3.83%
Short Ratio6.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.16%
Min EPS beat(2)-6.95%
Max EPS beat(2)6.63%
EPS beat(4)3
Avg EPS beat(4)12.58%
Min EPS beat(4)-6.95%
Max EPS beat(4)34.64%
EPS beat(8)6
Avg EPS beat(8)21.86%
EPS beat(12)7
Avg EPS beat(12)8.29%
EPS beat(16)11
Avg EPS beat(16)13.28%
Revenue beat(2)0
Avg Revenue beat(2)-10%
Min Revenue beat(2)-14.57%
Max Revenue beat(2)-5.44%
Revenue beat(4)1
Avg Revenue beat(4)-5.47%
Min Revenue beat(4)-14.57%
Max Revenue beat(4)0.34%
Revenue beat(8)1
Avg Revenue beat(8)-6.36%
Revenue beat(12)3
Avg Revenue beat(12)-5.39%
Revenue beat(16)7
Avg Revenue beat(16)-1.44%
PT rev (1m)0%
PT rev (3m)7.69%
EPS NQ rev (1m)-18.53%
EPS NQ rev (3m)-77.8%
EPS NY rev (1m)-7.93%
EPS NY rev (3m)12.82%
Revenue NQ rev (1m)1.66%
Revenue NQ rev (3m)2.19%
Revenue NY rev (1m)7.48%
Revenue NY rev (3m)6.26%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.16
P/FCF 73.36
P/OCF 43.99
P/B 4.53
P/tB 4.64
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.05
Fwd EYN/A
FCF(TTM)0.02
FCFY1.36%
OCF(TTM)0.03
OCFY2.27%
SpS1.13
BVpS0.29
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.86%
ROE -34.06%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.94%
FCFM 1.58%
ROA(3y)-16.33%
ROA(5y)-19.79%
ROE(3y)-57.26%
ROE(5y)-58.76%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.16%
GM growth 5Y-1.44%
F-Score5
Asset Turnover1.02
Health
Industry RankSector Rank
Debt/Equity 1.02
Debt/FCF 24.8
Debt/EBITDA N/A
Cap/Depr 163.87%
Cap/Sales 1.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2
Quick Ratio 1.35
Altman-Z -4.82
F-Score5
WACC8.9%
ROIC/WACCN/A
Cap/Depr(3y)132.31%
Cap/Depr(5y)95.58%
Cap/Sales(3y)1.64%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-5.09%
EPS Next 2Y22.7%
EPS Next 3Y28.85%
EPS Next 5YN/A
Revenue 1Y (TTM)11.25%
Revenue growth 3Y8.07%
Revenue growth 5Y16.5%
Sales Q2Q%16.34%
Revenue Next Year29.28%
Revenue Next 2Y18.91%
Revenue Next 3Y16.46%
Revenue Next 5YN/A
EBIT growth 1Y19.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year170.67%
EBIT Next 3Y60.42%
EBIT Next 5YN/A
FCF growth 1Y113.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y126.78%
OCF growth 3YN/A
OCF growth 5YN/A